Informations générales (source: ClinicalTrials.gov)
A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Interventional
Phase 3
Regeneron Pharmaceuticals (Voir sur ClinicalTrials)
juillet 2022
juin 2031
31 octobre 2024
This study is researching an experimental drug called REGN3767, also known as fianlimab
(R3767), when combined with another medication called REGN2810, also known as cemiplimab
(each individually called a "study drug" or called "study drugs" when combined).
The study is focused on patients with a type of skin cancer known as melanoma. The aims
of the study are to see how effective the combination of fianlimab and cemiplimab are in
treating the melanoma skin cancer, in comparison with a medication, pembrolizumab,
approved for the treatment of melanoma skin cancer in adults, and to observe any
similarities, or differences, in how the study drugs work in adolescent participants
compared with adult participants.
The study is looking at several other research questions, including:
- What side effects may happen from receiving the study drugs
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drugs (which could make the
drugs less effective or could lead to side effects). Antibodies are proteins that
are naturally found in the blood stream that fight infections.
- How administering the study drugs might improve quality of life
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Caroline ROBERT | 12/02/2024 15:56:04 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Ambroise Paré | Contact (sur clinicalTrials) | ||||
| AP-HP - Hôpital Avicenne | Contact (sur clinicalTrials) | ||||
| AP-HP - Hôpital Cochin | Contact (sur clinicalTrials) | ||||
| AP-HP - Hôpital Henri Mondor-Albert Chenevier | Contact (sur clinicalTrials) | ||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Hospitalier Universitaire De Grenoble Alpes Service Dermatologie - 38700 - Grenoble - France | Contact (sur clinicalTrials) | ||||
| Centre Hospitalier Universitaire de Nantes (CHU de Nantes) Hotel Dieu - 44000 - Nantes - France | Contact (sur clinicalTrials) | ||||
| Centre Leon Berard - 69373 - Lyon cedex 08 - France | Contact (sur clinicalTrials) | ||||
| CH Le Mans - Plateforme de recherche clinique - 72037 - Le Mans - France | Contact (sur clinicalTrials) | ||||
| Chru De Lille - 59037 - Lille Cedex - France | Contact (sur clinicalTrials) | ||||
| CHU Charles Nicolle Dermatologie - 76031 - Rouen - France | Contact (sur clinicalTrials) | ||||
| CHU de DIJON - Service de Dermatologie - 021000 - Dijon - France | Contact (sur clinicalTrials) | ||||
| CHU Estaing, Service de Dermatologie - 63003 - Clermont-Ferrand - France | Contact (sur clinicalTrials) | ||||
| CHU Jean MINJOZ - 25030 - Besancon Cedex - France | Contact (sur clinicalTrials) | ||||
| CHU Saint-Etienne - Hopital Nord - 42055 - Saint-Etienne - France | Contact (sur clinicalTrials) | ||||
| Clinique Sainte Anne/Strasbourg Oncologie Liberale - 67000 - Strasbourg - France | Contact (sur clinicalTrials) | ||||
| Hopital de la Miletrie Centre Hospitalier Universitaire de Poitiers - 86021 - Poitiers Cedex - France | Contact (sur clinicalTrials) | ||||
| HOPITAL SAINT ANDRE Chu De Bordeaux - 033075 - Bordeaux Cedex - France | Contact (sur clinicalTrials) | ||||
| Hospices Civils de Lyon - 69495 - Pierre Benite Cedex - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
1. Age ≥12 years on the date of providing informed consent
2. Patients with histologically confirmed unresectable Stage III and Stage IV
(metastatic) melanoma (AJCC, 8th revised edition) who have not received prior
systemic therapy for advanced unresectable disease
1. Patients who received adjuvant and/or neoadjuvant systemic therapies are
eligible if they did not have evidence of progression or recurrence of disease
and/or discontinued due to occurrence of unmanageable imAEs ≥ grade 3 (with the
exclusion of endocrinopathies which are fully controlled by hormone
replacement) while on such therapies. Also, patients must have had a
treatment-free and disease-free interval of >6 months. Accrual of these
patients is limited to approximately 10% of the total population enrolled.
2. Patients with acral and mucosal melanomas are eligible. Accrual will be limited
to 10% of the total population.
3. Measurable disease per RECIST v1.1
1. Previously irradiated lesions can only be counted as target lesions if they
have been demonstrated to progress and no other target lesion is available
2. Cutaneous lesions should be evaluated as non-target lesions
4. Performance status:
1. For adult patients: Eastern Cooperative Oncology Group (ECOG) performance
status (PS) 0 or 1
2. For pediatric patients: Karnofsky performance status ≥70 (patients ≥16 years)
or Lansky performance status ≥70 (patients ≤16 years)
5. Anticipated life expectancy of at least 3 months
Key
1. Age ≥12 years on the date of providing informed consent
2. Patients with histologically confirmed unresectable Stage III and Stage IV
(metastatic) melanoma (AJCC, 8th revised edition) who have not received prior
systemic therapy for advanced unresectable disease
1. Patients who received adjuvant and/or neoadjuvant systemic therapies are
eligible if they did not have evidence of progression or recurrence of disease
and/or discontinued due to occurrence of unmanageable imAEs ≥ grade 3 (with the
exclusion of endocrinopathies which are fully controlled by hormone
replacement) while on such therapies. Also, patients must have had a
treatment-free and disease-free interval of >6 months. Accrual of these
patients is limited to approximately 10% of the total population enrolled.
2. Patients with acral and mucosal melanomas are eligible. Accrual will be limited
to 10% of the total population.
3. Measurable disease per RECIST v1.1
1. Previously irradiated lesions can only be counted as target lesions if they
have been demonstrated to progress and no other target lesion is available
2. Cutaneous lesions should be evaluated as non-target lesions
4. Performance status:
1. For adult patients: Eastern Cooperative Oncology Group (ECOG) performance
status (PS) 0 or 1
2. For pediatric patients: Karnofsky performance status ≥70 (patients ≥16 years)
or Lansky performance status ≥70 (patients ≤16 years)
5. Anticipated life expectancy of at least 3 months
Key
1. Uveal melanoma
2. Ongoing or recent (within 2 years) evidence of an autoimmune disease that required
systemic treatment with immunosuppressive agents. The following are
non-exclusionary: vitiligo, childhood asthma that has resolved, residual
hypothyroidism that requires only hormone replacement, psoriasis not requiring
systemic treatment.
3. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B (HBV) or
hepatitis C virus (HCV) infection; or diagnosis of immunodeficiency that is related
to, or results in chronic infection
4. Unknown BRAF V600 mutation status as described in the protocol
5. Systemic immune suppression:
1. Use of immunosuppressive doses of corticosteroids (>10mg of prednisone per day
or equivalent) within 14 days of the first dose of study medication.
Physiologic replacement doses are allowed up to and including 10mg of
prednisone/day or equivalent. Inhaled or topical steroids are permitted, if
they are not for treatment of an autoimmune disorder.
2. Other clinically relevant forms of systemic immune suppression
6. Treatment with other anti-cancer therapy including immuno- therapy, chemotherapy,
major surgery or biological therapy within 21 days prior to the first dose of trial
treatment. Adjuvant hormonotherapy used for breast cancer or other hormone-sensitive
cancers in long term remission is allowed.
7. History or current evidence of significant (CTCAE Grade ≥2) local or systemic
infection (e. g., cellulitis, pneumonia, septicemia) requiring systemic antibiotic
treatment within 14 days prior to the first dose of trial medication.
8. Active or untreated brain metastases or spinal cord compression. Patients with
leptomeningeal disease are excluded. Patients with known brain metastases are
eligible if they:
1. Received radiotherapy or another appropriate standard therapy for the brain
metastases,
2. Have neurologically returned to baseline (except for residual signs and
symptoms related to the CNS treatment) for at least 14 days prior to enrollment
3. Did not require immunosuppressive doses of corticosteroids therapy (>10mg of
prednisone per day or equivalent) in the 14 days prior to enrollment
4. Are asymptomatic with a single untreated brain metastasis <10 mm in size
9. Participants with a history of myocarditis.
Note: Other protocol-defined Inclusion/ Exclusion criteria apply